A phase II study of denileukin diftitox (ONTAK) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Lilly, M
Kuriakose, P
Turturro, F
Berdeja, J
Kerr, R
Surendranathan, A
Black, J
Frankel, A
机构：
[1] Loma Linda Univ, Loma Linda, CA 92350 USA
[2] Henry Ford Hosp, Detroit, MI 48202 USA
[3] Louisiana State Univ, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA
[4] SW Reg Canc Ctr, Austin, TX USA
[5] Wake Forest Univ Hlth Sci, Winston Salem, NC USA
[6] Wake Forest Univ, Winston Salem, NC 27109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：597S / 597S
页数：1
相关论文
共 50 条
  • [41] Dramatic and sustained Hematologic complete remission with denileukin diftitox (ONTAK®) in a patient with refractory adult T-cell leukemia (ATL).
    Ziegler, SL
    Augustyniak, C
    Gordon, LI
    Evens, AM
    BLOOD, 2005, 106 (11) : 238B - 239B
  • [42] Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
    Marotta, G
    Bigazzi, C
    Lenoci, M
    Tozzi, M
    Bocchia, M
    Lauria, F
    HAEMATOLOGICA, 2000, 85 (12) : 1268 - 1270
  • [43] Fludarabine, Cyclophosphamide, and Alemtuzumab (FCC) In Relapsed/Refractory Patients with B-Cell Chronic Lymphocytic Leukemia (CLL): Final Report of the Italian Study
    Montillo, Marco
    Tedeschi, Alessandra
    Ricci, Francesca
    Zaccaria, Alfonso
    Crugnola, Monica
    Spriano, Mauro
    Spedini, PierAngelo
    Ilariucci, Fiorella
    Uziel, Lilj
    Attolico, Immacolata
    De Blasio, Angelo
    Vismara, Eleonora
    Morra, Enrica
    Petrizzi, Valeria Belsito
    BLOOD, 2010, 116 (21) : 595 - 596
  • [44] Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia
    Castagna, L
    Sarina, B
    Santoro, A
    BLOOD, 2003, 102 (06) : 2309 - 2309
  • [45] Phase II study of denileukin diftitox (Ontak®) for treatment of steroid resistant acute graft versus host disease
    Shaughnessy, PJ
    Bachier, C
    Freytes, C
    Callander, N
    Essell, J
    Grimley, M
    LeMaistre, CF
    BLOOD, 2003, 102 (11) : 715A - 715A
  • [46] Thalidomide is active alone and in combination with fludarabine in fludarabine-relapsed and refractory chronic lymphocytic leukemia.
    Furman, RR
    Allen, SL
    Leonard, JP
    Coleman, M
    Markis, JM
    Gabrilove, JL
    BLOOD, 2004, 104 (11) : 291B - 291B
  • [47] THE EXPRESSION OF TOLL-LIKE RECEPTORS IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.
    Rybka, J.
    Butrym, A.
    Wrobel, T.
    Bogucka-Fedorczuk, A.
    Poreba, R.
    Jazwiec, B.
    Fraczak, E.
    Kuliczkowski, K.
    HAEMATOLOGICA, 2016, 101 : 718 - 718
  • [48] Effects of cyclosporin A on refractory B-cell chronic lymphocytic leukemia
    Nishii, K
    Katayama, N
    Mitani, H
    Matsumoto, T
    Miwa, H
    Kita, K
    Shiku, H
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2000, 71 (01) : 59 - 65
  • [49] A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Ogawa, Yoshiaki
    Ogura, Michinori
    Suzuki, Tatsuya
    Ando, Kiyoshi
    Uchida, Toshiki
    Shirasugi, Yukari
    Tobinai, Kensei
    Lee, Je Hwan
    Kase, Masazumi
    Katsura, Koichi
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (02) : 164 - 170
  • [50] A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Yoshiaki Ogawa
    Michinori Ogura
    Tatsuya Suzuki
    Kiyoshi Ando
    Toshiki Uchida
    Yukari Shirasugi
    Kensei Tobinai
    Je Hwan Lee
    Masazumi Kase
    Koichi Katsura
    Tomomitsu Hotta
    International Journal of Hematology, 2013, 98 : 164 - 170
12345